Companies

Apyx Medical Corp

APYX · CIK 0000719135 · operating

$3.30+0.92%Last updated Mar 2, 8:48 PM

Key Statistics

Valuation

Market Cap$134.58M
P/E
Fwd P/E-9.16
PEG
P/S2.81
P/B21.16
EV/EBITDA-15.61
EV/Rev2.91

Profitability

Gross Margin61.04%
Op. Margin-39.18%
Net Margin-48.78%
ROE-165.12%
ROA-36.18%
FCF Margin-39.02%

Financial Health

Current Ratio5.26
Debt/Equity3.55
Free Cash Flow-$18.77M
Div. Yield

Growth & Other

Revenue Growth-8.11%
EPS Growth
Beta1.58
52W High$4.5
52W Low$0.755

About Apyx Medical Corp

Apyx Medical designs, manufactures, and sells electrosurgical devices that use helium plasma technology to cut, coagulate, and ablate soft tissue during surgical procedures. The company's core product platform consists of helium plasma generators paired with single-use handpieces and accessories designed for both open and minimally invasive surgical applications. These devices deliver radiofrequency energy through ionized helium gas to enable precise tissue interaction with minimal thermal damage to surrounding areas.

The company operates through two business segments. The Advanced Energy segment markets helium plasma technology devices under the Renuvion brand for cosmetic surgery applications and under the J-Plasma brand for hospital surgical markets, including general surgery, orthopedics, and otolaryngology. The Original Equipment Manufacturing segment develops and produces generators and related accessories for other medical device manufacturers on an outsourced basis.

Apyx Medical is headquartered in Clearwater, Florida, and operates with approximately 220 full-time employees. The company sells its products in the United States and internationally. Originally incorporated in 1982 as Bovie Medical Corporation, the company rebranded to Apyx Medical in January 2019 to reflect its focus on advanced energy-based surgical technology.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2024$-0.66-22.2%
2023$-0.54$-0.54+19.4%
2022$-0.67$-0.67-52.3%
2021$-0.44$-0.44
2020
2019$-0.58$-0.58-131.2%
2018$1.86$-100.00+1194.1%
2017$-0.17$-0.03-13.3%
2016$-0.15$-0.02-200.0%
2015$-0.05$0.34+83.9%
2014$-0.31$-1.03-121.4%
2013$-0.14$-0.25-800.0%
2012$0.02$0.04+100.0%
2011$0.01$0.01

Annual Reports (10-K) · 19 filings

Report DateFiledAccession Number
2024-12-312025-03-130001437749-25-007521SEC ↗
2023-12-312024-03-210000719135-24-000016SEC ↗
2022-12-312023-03-160000719135-23-000018SEC ↗
2021-12-312022-03-170000719135-22-000020SEC ↗
2020-12-312021-03-310000719135-21-000029SEC ↗
2019-12-312020-03-310000719135-20-000029SEC ↗
2018-12-312019-03-140001628280-19-002892SEC ↗
2017-12-312018-03-130000719135-18-000015SEC ↗
2016-12-312017-03-100000719135-17-000009SEC ↗
2015-12-312016-03-180001477932-16-009087SEC ↗
2014-12-312015-02-270001477932-15-001424SEC ↗
2013-12-312014-03-310001477932-14-001436SEC ↗
2012-12-312013-04-010001140361-13-014654SEC ↗
2011-12-312012-03-290001140361-12-017979SEC ↗
2010-12-312011-03-310001140361-11-019571SEC ↗
2009-12-312010-03-160001140361-10-012046SEC ↗
2008-12-312009-03-160001140361-09-007066SEC ↗
2007-12-312008-03-310001140361-08-008085SEC ↗
2006-12-312007-03-220000719135-07-000012SEC ↗